However, the cytoplasmic delocalization of METTL3 in CML, where it exerts an oncogenic role independent of its catalytic activity, could potentially limit the efficacy of these inhibitors. This evidence concerns the gene METTL3 and chronic myelogenous leukemia, BCR-ABL1 positive.